Cytoreductive surgery halves death risk in colorectal peritoneal metastasis.

Cytoreductive surgery markedly improves overall survival in colorectal peritoneal metastasis compared to modern systemic therapies alone. A systematic review of 3316 patients reveals a pooled hazard ratio of 0.447, indicating nearly a 55% reduction in the risk of death. This benefit persists across various palliative treatments, demonstrating robust effectiveness despite variations in therapy intensity. With moderate certainty of evidence, these findings challenge the current debate on surgical intervention in metastatic settings.